Status:
COMPLETED
18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants
Lead Sponsor:
University of Utah
Conditions:
Pancreatitis, Graft
Pancreatic Transplant Post-Transplant Dysfunction Rejection
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allogra...
Detailed Description
18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates s...
Eligibility Criteria
Inclusion
- 18 or over in age
- Have any type of pancreatic transplant
- Able to consent for 18F-Fluciclovine PET/CT scan
- For archived 18F-Fluciclovine PET/CT scan reviews, only scans of non-diabetic patients will be included.
Exclusion
- \- Patient with known prostate cancer
Key Trial Info
Start Date :
September 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 6 2022
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT04852523
Start Date
September 16 2021
End Date
October 6 2022
Last Update
September 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah Hospital
Salt Lake City, Utah, United States, 84132